SIC 2835 – In Vitro and In Vivo Diagnostic Substances
| Valuation | |
|---|---|
| Market Cap ($M) | 25.35 |
| Enterprise Value ($M) | 23.46 |
| Book Value ($M) | 3.69 |
| Book Value / Share | 0.09 |
| Price / Book | 6.88 |
| NCAV ($M) | 1.83 |
| NCAV / Share | 0.05 |
| Price / NCAV | 13.84 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.83 |
| Return on Assets (ROA) | -1.85 |
| Return on Equity (ROE) | -2.79 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 8.51 |
| Current Ratio | 8.51 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 2.63 |
| Assets | 4.48 |
| Liabilities | 0.80 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Shares Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock, Inc. | 4.90 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 994,288 | 3,451,434 | 28.81 | |
| 5,171,139 | 15,036,431 | 34.39 | |
| 1,036,586 | 2,272,578 | 45.61 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CAPR – Capricor Therapeutics, Inc. | CARA – Cara Therapeutics, Inc. |
| CASI – CASI Pharmaceuticals, Inc. | CDMO – Avid Bioservices, Inc. |
| CDTX – Cidara Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io